HC Wainwright Begins Coverage on Agios Pharmaceuticals (NASDAQ:AGIO)

Analysts at HC Wainwright began coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a note issued to investors on Monday, MarketBeat reports. The firm set a “buy” rating and a $58.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 64.82% from the stock’s previous close. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.42) EPS.

A number of other equities analysts also recently issued reports on the company. Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Scotiabank upped their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $35.19 on Monday. Agios Pharmaceuticals has a 52-week low of $27.14 and a 52-week high of $62.58. The firm’s 50 day moving average price is $34.01 and its 200-day moving average price is $42.92. The company has a market cap of $2.02 billion, a PE ratio of 3.10 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Erste Asset Management GmbH acquired a new position in Agios Pharmaceuticals in the third quarter valued at $97,199,000. Jefferies Financial Group Inc. purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth about $49,290,000. Vestal Point Capital LP acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $33,767,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth about $9,957,000. Finally, Paradigm Biocapital Advisors LP acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $9,084,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.